The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

“The applications of lentiviral vectors are diverse,” she says, pointing out that while 65% of the CDMO’s customers are developing immunotherapies, like CAR-Ts, TCRs, NK-CARs, NK-TCRs, TILs ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of ...

Download this application note to receive step-by-step guidance about optimizing and standardizing scalable lentiviral vector production and clarification. Sponsored by. Top Image Credit: ©iStock, ...

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 ...

ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer. Share.

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies.. The latest entry into the CDMO viral vector ...

Yet, despite their importance to the industry, current vector production processes are far from optimal, says Adriano Leuzzi, head of process development at Italy-based manufacturing and ...

GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ -- Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing ...

GAITHERSBURG, Md., May 2, 2025 /PRNewswire/ -- Vector BioMed (VBM), a leading lentiviral vector CDMO advancing access to gene therapies, will showcase its innovations at two major industry events ...

UCL leveraged ViroCell's expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ("ViroCell" ...